Name | Type | Posted | Actions |
|---|---|---|---|
Amendment_5to_the_RFP_-_10-18-2024_0005.pdf | Oct 18, 2024 | ||
Amendment_4_to_the_RFP_-_10-11-2024_0004.pdf | Oct 11, 2024 | ||
Amendment_3_to_the_RFP_-_10-08-2024_0003.pdf | Oct 8, 2024 | ||
Amendment_2_to_the_RFP_-_9-20-24_0002.pdf | Sep 20, 2024 | ||
Amendment_1_to_RFP_75N94024R00008_9-11-24_0001.pdf | Sep 11, 2024 | ||
Sol_75N94024R00008.pdf | Sep 4, 2024 |
A--BPCA Pediatric Trials Network
Contact and place of performance
OSINSKI, ELIZABETH J
Not specified
Best Pharmaceuticals for Children Act (BPCA) Pediatric Trials Network (PTN)
The National Institutes of Health, specifically the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), has issued solicitation 75N94024R00008 for the Best Pharmaceuticals for Children Act (BPCA) Pediatric Trials Network (PTN). This requirement falls under NAICS code 541715 for Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) and PSC AN11 for Health R&D Services, Health Care Services, and Basic Research. Elizabeth J. Osinski serves as the primary point of contact for this solicitation.
The primary purpose of this initiative is to support the Pediatric Trials Network in conducting clinical trials and research activities as mandated by the Best Pharmaceuticals for Children Act. The solicitation package includes the original request for proposals and five subsequent amendments issued between September 11, 2024, and October 18, 2024. Interested parties must submit their responses by the deadline of November 4, 2024. No specific set-aside designation is indicated for this procurement.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.